ICON PLC
ICLR Healthcare Diagnostics & Research
ICON PLC’s revenue for fiscal 2025 (year ended December 2025) was $8.3 billion, up 0.76% from fiscal 2024. In the quarter to June 2026, revenue grew 1.20%, EPS fell 59.3%, free cash flow grew 109.7% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years.
Follow ICLR
ICON PLC (ICLR) Piotroski F-score
ICON PLC's Piotroski F-score for fiscal 2025 is 6 out of 9: 6 of nine tests of profitability, leverage and efficiency passed, down from 7 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 6 | (1.00) |
| FY2024 | 7 | (1.00) |
| FY2023 | 8 | 1.00 |
| FY2022 | 7 | 4.00 |
| FY2021 | 3 | (2.00) |
| FY2020 | 5 | 0.00 |
| FY2019 | 5 | (2.00) |
| FY2018 | 7 | 1.00 |
| FY2017 | 6 | (1.00) |
| FY2016 | 7 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | 1.39% | 4.40% | Pass | 1 |
| Positive operating cash flow | 1.04b | 1.29b | Pass | 1 |
| Rising return on assets | 1.39% | 4.40% | Fail | 0 |
| Cash flow above net income | 806.87m | 547.53m | Pass | 1 |
| Falling long-term leverage | 0.17 | 0.20 | Pass | 1 |
| Rising current ratio | 1.10 | 1.24 | Fail | 0 |
| No new shares issued | 78,424,000 | 82,483,000 | Pass | 1 |
| Rising gross margin | 26.37% | 28.95% | Fail | 0 |
| Rising asset turnover | 0.50 | 0.49 | Pass | 1 |
| Piotroski F-score | Mixed | 6 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| DGX Quest Diagnostics Incorporated compare | 8 |
| LH Labcorp Holdings Inc. compare | 8 |
| MEDP Medpace Holdings, Inc. compare | 8 |
| QGEN QIAGEN N.V. compare | 8 |
| ICLR ICON PLC | 6 |
| RVTY Revvity Inc. compare | 6 |
| CRL Charles River Laboratories International, Inc. compare | 5 |
| GH Guardant Health, Inc. compare | 5 |
| TWST Twist Bioscience Corporation compare | 4 |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover